AIFA waxay cusboonaysiisay qaababka loo adeegsado unugyada difaaca jirka ee ka soo horjeeda COVID-19 marka loo eego caddeynta cusub ee suugaanta ee dhowaan la helay.
Gaar ahaan, ra'yi togan ayaa la siiyay adeegsiga antibody-ka sotrovimab kaas oo muujiyey saamiga faa'iidada / halista wanaagsan sidoo kale ka soo horjeedda kala duwanaanshaha wareegga ee SARS-CoV-2. Sidoo kale ansixinta antibody -kan cusub, habka oggolaanshaha si ku -meelgaar ah loogu qaybiyo Digreetada Wasiirka Caafimaadka ayaa la isticmaalay, sidaas darteedna antibody -kan ayaa lagu daray kuwa kale ee hore loo heli jiray (bamlanivamb / etesevimab iyo casirivimab / imdevimab).
Intaa waxaa sii dheer, natiijooyinka tijaabada caafimaad ee dib -u -soo -kabashada caalamiga ah ayaa la qiimeeyay, taas oo muujisay faa'iido marka la eego dhimashada iyo yareynta halista horumarka cudurka (dib -u -dhigista hawo -mareenka ama dhimashada) ee daaweynta casirivimab iyo imdevimab ee bukaannada qaangaarka ah ee isbitaalka COVID-19, xitaa daaweynta oksijiinta ee caadiga ah (oo aan ahayn heerar qulqul sarreeya oo aan ku jirin hawo-mareenka), iyo serology xun oo loogu talagalay ka-hortagga Spike IgG ee SARS-CoV-2. Sidaa darteed Wakaaladdu waxay go'aansatay inay kordhiso adeegsiga suurtagalka ah ee isku -darka casirivimab / imdevimab ee dad -weynaha.
Go'aaminta qaraabada waxaa lagu daabici doonaa Faafinta Rasmiga ah ee 6da Ogosto 2021 waxayna dhaqan geli doontaa laga bilaabo maalinta daabacaadda kadib.
Ugu dambayntii, iyada oo la tixgalinayo duruufaha faafa ee baahsanaanta kala duwanaanshaha SARS-CoV-2, oo si dhakhso leh loo beddelay toddobaadyadii la soo dhaafay, fiiro gaar ah ayaa loo siiyay xaqiiqda ah in ka-hortagga SARS-CoV-2 unugyada difaaca jirka ee monoclonal hadda la heli karo, iyada oo la soo bandhigayo tilmaamaha 'adeegsiga is -dul -saaran, way kala duwan yihiin midba midka kale, iyadoo lagu saleynayo caddeynta suugaanta ee dhowaan, awooddooda ah inay dhexdhexaadiyaan kala duwanaanshaha wareegga ee kala duwan. Dhammaan unugyada ka-hortagga SARS-CoV-2 ee laga heli karo Talyaaniga (bamlanivamb / etesevimab, casirivimab / imdevimab iyo sotrovimab) waxay hayaan dhaqdhaqaaq fayruus oo ku filan oo ka dhan ah alfa (nasab B.1.1.7) iyo delta (nasab B.1.617.2. 1.351), halka dhexdhexaadinta waxqabadka bamlanivamb / etesevimab, si ka duwan sida unugyada kale ee monoclonal (casirivimab / imdevimab iyo sotrovimab), ayaa si adag looga horjoogsadaa beta (B.1) iyo gamma (P.XNUMX). Sidaa darteed, aagagga juqraafiyeed ee ay ku jiraan wareegga beta iyo kala duwanaanshaha gamma, waxaa la soo jeediyay in la isticmaalo unugyada difaaca jirka monoclonal (casirivimab / imdevimab iyo sotrovimab) oo wax ku ool u ah dhammaan noocyada kala duwan ama in la hormariyo bilowga daweynta iyada oo genotyping / isku xigxiga.